- Home
- PMVP vs UNCY Comparison
PMVP vs UNCY Comparison
Compare PMVP & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- UNCY
- Stock Information
- Founded
- PMVP 2013
- UNCY 2016
- Country
- PMVP United States
- UNCY United States
- Employees
- PMVP 47
- UNCY N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- UNCY Health Care
- Exchange
- PMVP Nasdaq
- UNCY Nasdaq
- Market Cap
- PMVP 82.1M
- UNCY 74.2M
- IPO Year
- PMVP 2020
- UNCY 2021
- Fundamental
- Price
- PMVP $1.48
- UNCY $4.22
- Analyst Decision
- PMVP Strong Buy
- UNCY Strong Buy
- Analyst Count
- PMVP 1
- UNCY 4
- Target Price
- PMVP $5.00
- UNCY $63.75
- AVG Volume (30 Days)
- PMVP 364.5K
- UNCY 475.4K
- Earning Date
- PMVP 08-07-2025
- UNCY 08-14-2025
- Dividend Yield
- PMVP N/A
- UNCY N/A
- EPS Growth
- PMVP N/A
- UNCY N/A
- EPS
- PMVP N/A
- UNCY N/A
- Revenue
- PMVP N/A
- UNCY N/A
- Revenue This Year
- PMVP N/A
- UNCY N/A
- Revenue Next Year
- PMVP N/A
- UNCY $3,131.28
- P/E Ratio
- PMVP N/A
- UNCY N/A
- Revenue Growth
- PMVP N/A
- UNCY N/A
- 52 Week Low
- PMVP $0.81
- UNCY $2.83
- 52 Week High
- PMVP $1.82
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- PMVP 56.79
- UNCY 46.44
- Support Level
- PMVP $1.38
- UNCY $4.07
- Resistance Level
- PMVP $1.59
- UNCY $4.35
- Average True Range (ATR)
- PMVP 0.10
- UNCY 0.25
- MACD
- PMVP -0.00
- UNCY 0.04
- Stochastic Oscillator
- PMVP 65.52
- UNCY 36.94
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.